[PRTO] Proteon Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.95 Change: -0.1 (-4.88%)
Ext. hours: Change: 0 (0%)

chart PRTO

Refresh chart

Strongest Trends Summary For PRTO

PRTO is in the medium-term down -88% below S&P in 4 months. In the long-term down -97% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Proteon Therapeutics Inc develops pharmaceuticals to treat renal and vascular diseases. The company is developing PRT-201, a recombinant human elastase, which is in Phase III clinical trials for the treatment of radiocephalic arteriovenous fistula; and has completed a Phase I/II trial for the treatment of patients undergoing surgical placement of an arteriovenous graft. The company was founded in 2001 and is based in Waltham, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-3.12% ROE-3.23% ROI
Current Ratio30.65 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-55.18 M Cash From Operating Activities-3.87 M Gross Profit
Net Profit-4.58 M Operating Profit-4.62 M Total Assets80.93 M Total Current Assets80.73 M
Total Current Liabilities2.63 M Total Debt Total Liabilities2.63 M Total Revenue
Technical Data
High 52 week3.75 Low 52 week0.36 Last close0.38 Last change3.18%
RSI38.74 Average true range0.03 Beta0.51 Volume264.56 K
Simple moving average 20 days-6.12% Simple moving average 50 days-71.31% Simple moving average 200 days-80.9%
Performance Data
Performance Week4.44% Performance Month-25.62% Performance Quart-87.42% Performance Half-77.21%
Performance Year-81.66% Performance Year-to-date-83.44% Volatility daily3.77% Volatility weekly8.43%
Volatility monthly17.28% Volatility yearly59.85% Relative Volume121.33% Average Volume1.18 M
New High New Low-0%

News

2019-05-08 08:08:16 | Proteon Therapeutics: 1Q Earnings Snapshot

2019-05-08 08:00:00 | Proteon Therapeutics Announces First Quarter 2019 Financial Results

2019-04-19 10:49:43 | Proteon exploring sale after 2nd drug trial failure

2019-04-16 08:10:46 | The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

2019-04-15 16:30:00 | Proteon Therapeutics Announces Review of Potential Strategic Transactions

2019-03-28 08:00:00 | Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas

2019-03-13 08:17:27 | Proteon Therapeutics: 4Q Earnings Snapshot

2019-03-13 08:00:00 | Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results

2019-03-04 16:30:00 | Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th

2019-02-12 09:25:00 | 4 Healthcare Stocks Looking To Set February Highs

2019-01-24 08:00:00 | Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease

2018-12-20 10:49:59 | Does The Proteon Therapeutics, Inc. NASDAQ:PRTO Share Price Fall With The Market?

2018-11-16 07:35:00 | New Research Coverage Highlights Yum! Brands, TELUS, Unifi, Proteon Therapeutics, Sabine Royalty Trust, and Algonquin Power & Utilities — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-08 07:45:00 | Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th

2018-11-07 10:03:42 | Proteon Therapeutics: 3Q Earnings Snapshot

2018-11-07 08:00:00 | Proteon Therapeutics Announces Third Quarter 2018 Financial Results

2018-09-17 15:10:45 | Is Proteon Therapeutics Inc NASDAQ:PRTO A Strong Healthcare Bet?

2018-08-07 08:11:39 | Proteon Therapeutics: 2Q Earnings Snapshot

2018-08-07 08:00:00 | Proteon Therapeutics Announces Second Quarter 2018 Financial Results

2018-06-14 08:00:00 | Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

2018-05-15 19:07:10 | Proteon Therapeutics Inc’s NASDAQ:PRTO Earnings Dropped -27.47%, How Did It Fare Against The Industry?

2018-05-10 07:05:00 | Blog Exposure - Proteon Extended Long-term Contract with Lonza for Commercial Supply of Vonapanitase's Active Pharmaceutical Ingredient

2018-05-09 08:24:32 | Proteon Therapeutics: 1Q Earnings Snapshot

2018-05-09 08:10:00 | Proteon Therapeutics Announces First Quarter 2018 Financial Results

2018-05-08 07:00:00 | Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply

2018-03-14 08:06:23 | Proteon Therapeutics Inc NASDAQ:PRTO: Are Analysts Optimistic?

2018-03-14 08:00:00 | Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results

2018-03-06 16:45:00 | Proteon Therapeutics to Present at Two Upcoming Investor Conferences

2018-03-05 17:00:00 | Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase

2017-11-08 08:00:00 | Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th

2017-11-07 08:29:48 | Proteon Therapeutics reports 3Q loss

2017-11-07 08:00:00 | Proteon Therapeutics Announces Third Quarter 2017 Financial Results

2017-09-05 07:45:00 | Proteon Therapeutics to Present at the Baird 2017 Global Healthcare Conference September 7, 2017

2017-08-07 19:50:41 | Proteon Therapeutics reports 2Q loss

2017-08-07 17:00:00 | Proteon Therapeutics Announces Second Quarter 2017 Financial Results

2017-08-02 19:30:00 | Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing

2017-06-22 09:32:07 | Proteon Therapeutics Announces $22.0 Million Private Placement

2017-06-15 08:00:00 | Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st

2017-05-10 08:08:28 | Proteon Therapeutics reports 1Q loss

2017-05-10 08:00:00 | Proteon Therapeutics Announces First Quarter 2017 Financial Results

2017-05-10 07:30:00 | Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase

2017-05-02 16:40:00 | Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial

2017-05-01 08:00:00 | Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th

2017-04-05 20:01:00 | Lifshitz & Miller LLP Announces Investigation of BRF S.A., Innoviva, Inc., Panera Bread Company, PRA Group, Inc., Proteon Therapeutics, Inc., tronc, Inc. and Vuzix Corporation

2017-03-23 16:41:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Proteon Therapeutics, Inc.

2017-03-22 06:04:15 | PROTEON THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits

2017-03-17 09:20:08 | Proteon CEO: New trial could be a path to market

2017-03-17 07:55:00 | Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd

2017-03-16 08:01:27 | Proteon Therapeutics reports 4Q loss

2017-03-16 07:16:03 | PROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,